1
|
Shabbir A, Iqbal MS, Saeed MZ, Rashid F. Synthesis and in vitro evaluation of cross-linked tragacanthin nanofibers as implants for delivery of cisplatin to hepatocellular carcinoma. Heliyon 2024; 10:e37304. [PMID: 39319154 PMCID: PMC11419852 DOI: 10.1016/j.heliyon.2024.e37304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2024] [Revised: 08/29/2024] [Accepted: 08/30/2024] [Indexed: 09/26/2024] Open
Abstract
There is growing interest in the use of electrospun polymeric nanofibers in drug delivery systems due to their remarkable surface-to-volume ratio, which enhances the processes of drug loading, specific cell binding and proliferation. The preferred polymers for drug delivery must be biocompatible and biodegradable. Gum tragacanth is one of the materials of choice for drug delivery. This work aimed at cross-linking the tragacanthin, the water-soluble fraction of gum tragacanth, with glutaraldehyde, synthesis of the cross-linked nanofibers and evaluating their properties to encapsulate and deliver a drug using caffeine as a model drug in the first place. The nanofibers were then loaded with cisplatin and evaluated against HepG2 cell line. The drug-loaded nanofibers (dia. 0.841 μm) were prepared by electrospinning using glutaraldehyde as the cross-linker and glycerol as a plasticizer and characterized by scanning electron microscopy, Fourier transform-infrared spectroscopy, electronic spectroscopy, 1HNMR, powder X-ray diffraction analysis, and thermogravimetric analysis. They released the encapsulated drugs in a sustained manner at pH 7.4 over 4.5 days (∼275 h with ∼80 % release) following Higuchi (cisplatin) and Hixon-Crowell (caffeine) kinetics. In a cytotoxicity assay against HepG2 cell line the cisplatin-loaded nanofibers exhibited enhanced activity compared to that with the standard cisplatin and in the caspase activity assay it activated caspase 3 to a higher extent and 8 and 9 to double the extent (4-fold) of cisplatin, suggesting a higher apoptotic activity by the nanoformulation than the standard cisplatin. Thus, nanoformulation appeared to be a potential candidate for treating hepatocellular carcinoma as an implant.
Collapse
Affiliation(s)
- Anam Shabbir
- Department of Chemistry, Forman Christian College, Lahore, 54600, Pakistan
| | | | | | - Farooq Rashid
- Health Physics Division, PINSTECH, P.O. Nilore, Islamabad, Pakistan
| |
Collapse
|
2
|
Baghdasaryan A, Liu H, Ren F, Hsu R, Jiang Y, Wang F, Zhang M, Grigoryan L, Dai H. Intratumor injected gold molecular clusters for NIR-II imaging and cancer therapy. Proc Natl Acad Sci U S A 2024; 121:e2318265121. [PMID: 38261618 PMCID: PMC10835035 DOI: 10.1073/pnas.2318265121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 12/21/2023] [Indexed: 01/25/2024] Open
Abstract
Surgical resections of solid tumors guided by visual inspection of tumor margins have been performed for over a century to treat cancer. Near-infrared (NIR) fluorescence labeling/imaging of tumor in the NIR-I (800 to 900 nm) range with systemically administrated fluorophore/tumor-targeting antibody conjugates have been introduced to improve tumor margin delineation, tumor removal accuracy, and patient survival. Here, we show Au25 molecular clusters functionalized with phosphorylcholine ligands (AuPC, ~2 nm in size) as a preclinical intratumorally injectable agent for NIR-II/SWIR (1,000 to 3,000 nm) fluorescence imaging-guided tumor resection. The AuPC clusters were found to be uniformly distributed in the 4T1 murine breast cancer tumor upon intratumor (i.t.) injection. The phosphocholine coating afforded highly stealth clusters, allowing a high percentage of AuPC to fill the tumor interstitial fluid space homogeneously. Intra-operative surgical navigation guided by imaging of the NIR-II fluorescence of AuPC allowed for complete and non-excessive tumor resection. The AuPC in tumors were also employed as a photothermal therapy (PTT) agent to uniformly heat up and eradicate tumors. Further, we performed in vivo NIR-IIb (1,500 to 1,700 nm) molecular imaging of the treated tumor using a quantum dot-Annexin V (QD-P3-Anx V) conjugate, revealing cancer cell apoptosis following PTT. The therapeutic functionalities of AuPC clusters combined with rapid renal excretion, high biocompatibility, and safety make them promising for clinical translation.
Collapse
Affiliation(s)
- Ani Baghdasaryan
- Department of Chemistry and Bio-X, Stanford University, Stanford, CA94305
| | - Haoran Liu
- Department of Chemistry and Bio-X, Stanford University, Stanford, CA94305
| | - Fuqiang Ren
- Department of Chemistry and Bio-X, Stanford University, Stanford, CA94305
| | - RuSiou Hsu
- Department of Chemistry and Bio-X, Stanford University, Stanford, CA94305
| | - Yingying Jiang
- Department of Chemistry and Bio-X, Stanford University, Stanford, CA94305
| | - Feifei Wang
- Department of Chemistry and Bio-X, Stanford University, Stanford, CA94305
| | - Mengzhen Zhang
- Department of Chemistry and Bio-X, Stanford University, Stanford, CA94305
| | - Lilit Grigoryan
- Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA94305
| | - Hongjie Dai
- Department of Chemistry and Bio-X, Stanford University, Stanford, CA94305
| |
Collapse
|
3
|
Acute toxicity of C60–Cis-Pt nanocomplex in vivo. APPLIED NANOSCIENCE 2022. [DOI: 10.1007/s13204-021-01680-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Kim J, Choi Y, Yang S, Lee J, Choi J, Moon Y, Kim J, Shim N, Cho H, Shim MK, Jeon S, Lim DK, Yoon HY, Kim K. Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses. Pharmaceutics 2022; 14:pharmaceutics14030474. [PMID: 35335852 PMCID: PMC8954063 DOI: 10.3390/pharmaceutics14030474] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 02/13/2022] [Accepted: 02/15/2022] [Indexed: 02/05/2023] Open
Abstract
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough to induce sufficient ICD, and also does not guarantee the safety of chemotherapeutics. To overcome the disadvantages of the conventional approach, we used doxorubicin (DOX) as an ICD inducer, and poly(lactic-co-glycolic acid) (PLGA)-based nanomedicine platform for controlled release of DOX. The diameter of 138.7 nm of DOX-loaded PLGA nanoparticles (DP-NPs) were stable for 14 days in phosphate-buffered saline (PBS, pH 7.4) at 37 °C. Furthermore, DOX was continuously released for 14 days, successfully inducing ICD and reducing cell viability in vitro. Directly injected DP-NPs enabled the remaining of DOX in the tumor site for 14 days. In addition, repeated local treatment of DP-NPs actually lasted long enough to maintain the enhanced antitumor immunity, leading to increased tumor growth inhibition with minimal toxicities. Notably, DP-NPs treated tumor tissues showed significantly increased maturated dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs) population, showing enhanced antitumor immune responses. Finally, the therapeutic efficacy of DP-NPs was maximized in combination with an anti-programmed death-ligand 1 (PD-L1) antibody (Ab). Therefore, we expect therapeutic efficacies of cancer CIT can be maximized by the combination of DP-NPs with immune checkpoint blockade (ICB) by achieving proper therapeutic window and continuously inducing ICD, with minimal toxicities.
Collapse
Affiliation(s)
- Jeongrae Kim
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Yongwhan Choi
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Suah Yang
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Jaewan Lee
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Jiwoong Choi
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Yujeong Moon
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Jinseong Kim
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Nayeon Shim
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Hanhee Cho
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Man Kyu Shim
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Sangmin Jeon
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Dong-Kwon Lim
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
| | - Hong Yeol Yoon
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
| | - Kwangmeyung Kim
- KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Korea; (J.K.); (Y.C.); (S.Y.); (J.L.); (J.C.); (J.K.); (N.S.); (D.-K.L.)
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea; (Y.M.); (H.C.); (M.K.S.); (S.J.); (H.Y.Y.)
- Correspondence: ; Tel.: +82-2-958-5916
| |
Collapse
|
5
|
Gao L, Cai S, Cai A, Zhao Y, Xu T, Ma Y, Xu Y, Wang Y, Wang H, Hu Y. The improved antitumor efficacy of continuous intratumoral chemotherapy with cisplatin-loaded implants for the treatment of sarcoma 180 tumor-bearing mice. Drug Deliv 2019; 26:208-215. [PMID: 30835582 PMCID: PMC6407574 DOI: 10.1080/10717544.2019.1574938] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Cisplatin is the most commonly used antitumor drug in the chemotherapy of a variety of malignancies. However, the severe side effects and drug resistance limit its clinical application. The aim of this study was to develop PLGA-based cisplatin-loaded implants and evaluate the antitumor efficacy of continuous intratumoral chemotherapy with the implants. The cisplatin-loaded implants were prepared by the direct compression method and characterized regarding drug content, micromorphology, in vitro and in vivo drug release profiles. Furthermore, the antitumor activity of the implants was conducted in sarcoma 180 tumor-bearing mice. The SEM images showed smooth surface of the implants and the mean drug content of the tested implants was (37.7% ± 0.5%, w/w). Both in vitro and in vivo release profiles of the implants were characterized by initial burst release followed by the sustained-release of cisplatin. Intratumoral implantation of the cisplatin-loaded implants could effectively inhibit the tumor growth. Additionally, intratumoral chemotherapy with the implants significantly reduced the systemic toxicity compared with intravenous injection of cisplatin. It is worth noting that an increase in the dose of the implants led to a higher tumor suppression rate without additional systemic toxicity. These results demonstrated that cisplatin-loaded implants enhanced the antitumor efficacy and reduced the dose-related side effects in sarcoma 180 tumor-bearing mice.
Collapse
Affiliation(s)
- Li Gao
- a School of Food and Biological Engineering , Hefei University of Technology , Hefei , People's Republic of China
| | - Shang Cai
- b Department of Bone Disease and Bone Tumors Surgery , First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China
| | - Awei Cai
- b Department of Bone Disease and Bone Tumors Surgery , First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China
| | - Yang Zhao
- c Department of Pathology , The Second People's Hospital of Hefei , Hefei , People's Republic of China
| | - Tangbing Xu
- d Department of Orthopeadic Surgery , Fourth Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China
| | - Yan Ma
- a School of Food and Biological Engineering , Hefei University of Technology , Hefei , People's Republic of China
| | - Yan Xu
- a School of Food and Biological Engineering , Hefei University of Technology , Hefei , People's Republic of China
| | - Yuan Wang
- b Department of Bone Disease and Bone Tumors Surgery , First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China
| | - Hao Wang
- b Department of Bone Disease and Bone Tumors Surgery , First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China
| | - Yong Hu
- b Department of Bone Disease and Bone Tumors Surgery , First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China
| |
Collapse
|
6
|
Maharajan K. Feasibility of local administration of chemotherapeutic drugs as an effective adjuvant therapy in primary, recurrent and metastatic extradural tumours of the spine-review. JOURNAL OF SPINE SURGERY (HONG KONG) 2019; 5:273-284. [PMID: 31380482 PMCID: PMC6626732 DOI: 10.21037/jss.2019.04.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Accepted: 04/17/2019] [Indexed: 06/10/2023]
Abstract
Present day multimodality treatment with advances in systemic chemotherapy and radiotherapy has increased the survival of patients significantly even in those primary tumours which were once considered to have a poor prognosis. However, local recurrence can severely jeopardise the quality of life and even reduce survival. Hence local recurrence is considered as the worst complication in the management of spinal tumours and the need to achieving adequate local tumour control cannot be overemphasised. Techniques like en bloc resections which significantly reduce the chances of local recurrence are always not possible due to anatomical and technical reasons and sometimes, not feasible in debilitated patients. Local administration of chemotherapeutic drugs has already been recognised as a treatment strategy in the management of bladder and brain tumours. In this literature review, an attempt is made to explore the available evidence in the English literature for local administration of chemotherapeutic drugs in the surgical management of primary, recurrent and metastatic spinal tumours.
Collapse
|
7
|
Yavuz B, Zeki J, Taylor J, Harrington K, Coburn JM, Ikegaki N, Kaplan DL, Chiu B. Silk Reservoirs for Local Delivery of Cisplatin for Neuroblastoma Treatment: In Vitro and In Vivo Evaluations. J Pharm Sci 2019; 108:2748-2755. [PMID: 30905702 DOI: 10.1016/j.xphs.2019.03.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 03/12/2019] [Accepted: 03/14/2019] [Indexed: 10/27/2022]
Abstract
Neuroblastoma is the most common extracranial childhood tumor, and current treatment requires surgical resection and multidrug chemotherapy. Local, perioperative delivery of chemotherapeutics is a promising treatment method for solid tumors that require surgical removal. In this study, we have aimed to develop a controlled-release implant system to deliver cisplatin in tumor or tumor resection area. Silk fibroin, a biodegradable, nonimmunogenic biopolymer was used to encapsulate different doses of cisplatin in a reservoir system. The physical integrity of the reservoirs was characterized by evaluating the crystalline structure of silk secondary structure using FTIR spectroscopy. The in vitro release of cisplatin was evaluated in phosphate-buffered saline at 37°C, and the reservoirs were able to release the drug up to 30 days. The cytotoxicity of cisplatin and cisplatin reservoirs were tested on KELLY cells. Cytotoxicity data showed 3.2 μg/mL cisplatin was required to kill 50% of the cell population, and the released cisplatin from the silk reservoirs showed significant cytotoxicity up to 21 days. Intratumoral implantation of silk reservoirs into an orthotopic neuroblastoma mouse model decreased tumor growth significantly when compared with control subjects. These results suggest that silk reservoirs are promising carriers for cisplatin delivery to the tumor site.
Collapse
Affiliation(s)
- Burcin Yavuz
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155
| | - Jasmine Zeki
- Department of Surgery, Stanford University, Stanford, California 94305
| | - Jordan Taylor
- Department of Surgery, Stanford University, Stanford, California 94305
| | - Kristin Harrington
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155
| | - Jeannine M Coburn
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155; Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, Massachusetts 01609
| | - Naohiko Ikegaki
- Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, Illinois 60612
| | - David L Kaplan
- Department of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155.
| | - Bill Chiu
- Department of Surgery, Stanford University, Stanford, California 94305.
| |
Collapse
|
8
|
Seah GL, Yu JH, Yang MY, Kim WJ, Kim JH, Park K, Cho JW, Kim JS, Nam YS. Low-power and low-drug-dose photodynamic chemotherapy via the breakdown of tumor-targeted micelles by reactive oxygen species. J Control Release 2018; 286:240-253. [PMID: 30071252 DOI: 10.1016/j.jconrel.2018.07.046] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Revised: 07/27/2018] [Accepted: 07/29/2018] [Indexed: 12/31/2022]
Abstract
Tumor-targeted delivery of anticancer agents using nanocarriers has been explored to increase the therapeutic index of cancer chemotherapy. However, only a few nanocarriers are clinically available because the physiological complexity often compromises their ability to target, penetrate, and control the release of drugs. Here, we report a method which dramatically increases in vivo therapeutic drug efficacy levels through the photodynamic degradation of tumor-targeted nanocarriers. Folate-decorated poly(ethylene glycol)-polythioketal micelles are prepared to encapsulate paclitaxel and porphyrins. Photo-excitation generates reactive oxygen species within the micelles to cleave the polythioketal backbone efficiently and facilitate drug release only at the illuminated tumor site. Intravenous injection of a murine xenograft model with a low dose of paclitaxel within the micelles, one-milligram drug per kg (mouse), corresponding to an amount less than that of Taxol by one order of magnitude, induces dramatic tumor regression without any acute systemic inflammation responses or organ toxicity under low-power irradiation (55 mW cm-2) at 650 nm.
Collapse
Affiliation(s)
- Geok Leng Seah
- Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Jeong Heon Yu
- Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Moon Young Yang
- Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea
| | - Woo Jin Kim
- Pathology Research Center, Department of Jeonbuk Inhalation Research, Korea Institute of Toxicology, 30 Baekhak-1-gil, Jeongup, Jeonbuk 56212, Republic of Korea
| | - Jin-Ho Kim
- Samsung Medical Center, Samsung Biomedical Research Institute, Irwon-dong, Gangnam-gu, Seoul 06351, Republic of Korea
| | - Keunchil Park
- Samsung Medical Center, Samsung Biomedical Research Institute, Irwon-dong, Gangnam-gu, Seoul 06351, Republic of Korea; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Irwon-dong, Gangnam-gu, Seoul 06351, Republic of Korea
| | - Jae-Woo Cho
- Pathology Research Center, Department of Jeonbuk Inhalation Research, Korea Institute of Toxicology, 30 Baekhak-1-gil, Jeongup, Jeonbuk 56212, Republic of Korea
| | - Jee Seon Kim
- Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea.
| | - Yoon Sung Nam
- Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea; KAIST Institute for the NanoCentury, Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea.
| |
Collapse
|
9
|
Seah GL, Yu JH, Koo BI, Lee DJ, Nam YS. Cancer-targeted reactive oxygen species-degradable polymer nanoparticles for near infrared light-induced drug release. J Mater Chem B 2018; 6:7737-7749. [DOI: 10.1039/c8tb02323a] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Nanocarriers can be translocated to the peripheral region of tumor tissues through the well-known enhanced permeability and retention effects.
Collapse
Affiliation(s)
- Geok Leng Seah
- Department of Material Science and Engineering
- Korea Advanced Institute of Science and Technology
- Daejeon
- Republic of Korea
| | - Jeong Heon Yu
- Department of Material Science and Engineering
- Korea Advanced Institute of Science and Technology
- Daejeon
- Republic of Korea
| | - Bon Il Koo
- Department of Material Science and Engineering
- Korea Advanced Institute of Science and Technology
- Daejeon
- Republic of Korea
| | - Dong Jae Lee
- Department of Material Science and Engineering
- Korea Advanced Institute of Science and Technology
- Daejeon
- Republic of Korea
| | - Yoon Sung Nam
- Department of Material Science and Engineering
- Korea Advanced Institute of Science and Technology
- Daejeon
- Republic of Korea
- KAIST Institute for NanoCentury
| |
Collapse
|
10
|
Browning RJ, Reardon PJT, Parhizkar M, Pedley RB, Edirisinghe M, Knowles JC, Stride E. Drug Delivery Strategies for Platinum-Based Chemotherapy. ACS NANO 2017; 11:8560-8578. [PMID: 28829568 DOI: 10.1021/acsnano.7b04092] [Citation(s) in RCA: 150] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Few chemotherapeutics have had such an impact on cancer management as cis-diamminedichloridoplatinum(II) (CDDP), also known as cisplatin. The first member of the platinum-based drug family, CDDP's potent toxicity in disrupting DNA replication has led to its widespread use in multidrug therapies, with particular benefit in patients with testicular cancers. However, CDDP also produces significant side effects that limit the maximum systemic dose. Various strategies have been developed to address this challenge including encapsulation within micro- or nanocarriers and the use of external stimuli such as ultrasound to promote uptake and release. The aim of this review is to look at these strategies and recent scientific and clinical developments.
Collapse
Affiliation(s)
- Richard J Browning
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford , Oxford OX1 2JD, United Kingdom
| | | | | | | | | | - Jonathan C Knowles
- Department of Nanobiomedical Science and BK21 Plus NBM, Global Research Center for Regenerative Medicine, Dankook University , 518-10 Anseo-dong, Dongnam-gu, Cheonan, Chungcheongnam-do, Republic of Korea
- The Discoveries Centre for Regenerative and Precision Medicine, UCL Campus , Gower Street, London WC1E 6BT, United Kingdom
| | - Eleanor Stride
- Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford , Oxford OX1 2JD, United Kingdom
| |
Collapse
|
11
|
Llombart-Blanco R, Villas C, Silva Á, Aldaz A, Navarro I, Forteza J, Algarra SM, Alfonso M. Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs. EUROPEAN SPINE JOURNAL : OFFICIAL PUBLICATION OF THE EUROPEAN SPINE SOCIETY, THE EUROPEAN SPINAL DEFORMITY SOCIETY, AND THE EUROPEAN SECTION OF THE CERVICAL SPINE RESEARCH SOCIETY 2017; 26:3216-3224. [DOI: 10.1007/s00586-017-4980-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/14/2016] [Revised: 01/16/2017] [Accepted: 01/24/2017] [Indexed: 11/29/2022]
|
12
|
Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model. Ther Deliv 2016; 7:201-12. [PMID: 27010983 DOI: 10.4155/tde-2015-0008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hepatocellular carcinomas are frequently nonresponsive to systemically delivered drugs. Local delivery provides an alternative to systemic administration, maximizing the dose delivered to the tumor, achieving sustained elevated concentrations of the drug, while minimizing systemic exposure. RESULTS Ultrasound-guided deposition of doxorubicin (Dox)-eluting in situ forming implants (ISFI) in an orthotopic tumor model significantly lowers systemic drug levels. As much as 60 µg Dox/g tumors were observed 21 days after ISFI injection. Tumors treated with Dox implants also showed a considerable reduction in progression at 21 days. CONCLUSION Dox-eluting ISFIs provide a promising platform for the treatment of hepatocellular carcinomas by which drug can be delivered directly into the lesion, bypassing distribution and elimination by the circulatory system.
Collapse
|
13
|
New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect. Phys Med 2014; 31:25-30. [PMID: 25492359 DOI: 10.1016/j.ejmp.2014.11.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2014] [Revised: 11/18/2014] [Accepted: 11/19/2014] [Indexed: 12/25/2022] Open
Abstract
We predict, for the first time, that by using United States Food and Drug Administration approved concentrations of cisplatin, major radiosensitization may be achieved via photoelectric mechanism during concomitant chemoradiotherapy (CCRT). Our analytical calculations estimate that radiotherapy (RT) dose to cancer cells may be enhanced via this mechanism by over 100% during CCRT. The results proffer new potential for significantly enhancing CCRT via an emerging clinical scenario, where the cisplatin is released in-situ from RT biomaterials loaded with cisplatin nanoparticles.
Collapse
|
14
|
Ghosh S, Ucer KB, D'Agostino R, Grant K, Sirintrapun J, Thomas MJ, Hantgan R, Bharadwaj M, Gmeiner WH. Non-covalent assembly of meso-tetra-4-pyridyl porphine with single-stranded DNA to form nano-sized complexes with hydrophobicity-dependent DNA release and anti-tumor activity. NANOMEDICINE : NANOTECHNOLOGY, BIOLOGY, AND MEDICINE 2014; 10:451-61. [PMID: 23988714 PMCID: PMC3946208 DOI: 10.1016/j.nano.2013.07.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2013] [Accepted: 07/22/2013] [Indexed: 11/30/2022]
Abstract
DNA and porphyrin based therapeutics are important for anti-cancer treatment. The present studies demonstrate single-stranded DNA (ssDNA) assembles with meso-tetra-4-pyridyl porphine (MTP) forming porphyrin:DNA nano-complexes (PDN) that are stable in aqueous solution under physiologically relevant conditions and undergo dissociation with DNA release in hydrophobic environments, including cell membranes. PDN formation is DNA-dependent with the ratio of porphyrin:DNA being approximately two DNA nucleobases per porphyrin. PDN produce reactive oxygen species (ROS) in a light-dependent manner under conditions that favor nano-complex dissociation in the presence of hydrophobic solvents. PDN induce light-dependent cytotoxicity in vitro and anti-tumor activity towards bladder cancer xenografts in vivo. Light-dependent, PDN-mediated cell death results from ROS-mediated localized membrane damage due to lipid peroxidation with mass spectrometry indicating the generation of the lipid peroxidation products 9- and 13-hydroxy octadecanoic acid. Our results demonstrate that PDN have properties useful for therapeutic applications, including cancer treatment. FROM THE CLINICAL EDITOR In this study, porphyrin-DNA nanocomplexes were investigated as anti-cancer therapeutics inducing ROS production in a light-dependent manner. Efficacy is demonstrated in vitro as well as a in a bladder cancer xenograft model.
Collapse
Affiliation(s)
- Supratim Ghosh
- Program in Molecular Genetics, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Kamil B Ucer
- Department of Physics, Wake Forest University, Winston-Salem, NC, USA
| | - Ralph D'Agostino
- Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Ken Grant
- Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Joseph Sirintrapun
- Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Michael J Thomas
- Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Roy Hantgan
- Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Manish Bharadwaj
- Department of Genrontology, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - William H Gmeiner
- Program in Molecular Genetics, Wake Forest School of Medicine, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA; Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA.
| |
Collapse
|